NASDAQ · AXGN

Axogen, Inc.

$41.14 +$1.65 (+4.18%) 1D After hours

Key Metrics

$2.10B
Market cap
P/E · TTM
$238.11M
Revenue · TTM
−$31.45M
Net income
EPS · TTM $-0.70
Dividend yield
Free cash flow $9.28M
Beta · 1Y 0.80
EBITDA · TTM −$2.48M
Gross margin 75.0%

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Apr 8
    The stock moved +9.7% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Apr 8
  • Feb 24
    The stock moved -8.1% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Feb 24

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$2.10B
Enterprise value$2.00B
Shares outstanding53.2M
52-wk range$12.39 – $46.95
Avg volume · 20D473.5K
Net cash $101.60M
Book value / share$5.42
IndustryElectromedical & Electrotherapeutic Apparatus
ExchangeNASDAQ
About Axogen, Inc.
IPO dateDec 17, 1986
Employees622

Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically and economically effective repair solutions for surgeons and health care providers.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S8.82
P/FCF226.34
EV/EBITDA
EV/Sales8.39
Graham №

Profitability

Gross 75.0%
Operating -3.8%
Net -13.2%
FCF 3.9%
ROE / ROIC -18.0% · —

Financial Health

Current ratio7.10
Quick ratio5.33
Debt / equity0.00
Debt / EBITDA 0.00Low leverage
Net cash $101.60M
Working capital$158.70M

Cash Flow · TTM

Operating CF $15.56M
Capex −$6.28M
Free cash flow $9.28M
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

5 / 9
Middling fundamentals · 5 of 9 signals passing

Altman Z-Score

28.0
Safe zone (> 2.99) · bankruptcy risk negligible

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings